NCI-2023-03815

A Phase 1 Study of ASP1002 in Participants with Metastatic or Locally Advanced Solid Tumors

This is a Phase 1 research study testing a new experimental drug called ASP1002 in people who have solid tumors that are either metastatic (have spread to other parts of the body) or locally advanced (grown too large or too close to vital organs to be removed by surgery). ASP1002 targets cancer-specific pathways or stimulate the immune system to fight cancer more effectively. Since these cancers are typically hard to treat and may not respond well to existing therapies, this trial is exploring whether ASP1002 could become a new treatment option.

Phase 1: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05719558

Clinical Trial Site: Sinai

To see all available clinical trials click here.